三维适形放疗中期原发性肝癌56例分析  

The analysis of three-dimensional conformal radiotherapy for 56 cases of middle stage Primary hepatocellular carcinoma

作　　者：温尊北 苏德庆 梁宇学 林启富 陈宗友 WEN Zunbei, SU Deqing, LIANG Yuxie, CHEN Zhongyou, LIN Qifu （The first Department of radiation Oncology, Gaozhou people＇ s hospital Guangdong Gaozhou, 525200, China.）

机构地区：广东高州市人民医院放疗一科,525200

出　　处：《中外健康文摘：医药月刊》2007年第6期12-14,共3页

摘　　要：目的探讨三维适形放射治疗在中期原发性肝癌中的治疗效价值。方法2002年1月～2006年12月,对诊断为中期原发性肝癌56例,采用RAHD7.0三维治疗计划系统进行靶区勾画,设计治疗计划,用SIMENS加速器6MVX线配适形铅挡块进行照射,分割剂量2.5Gy,照射次数为16～26次,中位次数20次,每周5次,每日一次,总剂量40～65Gy。结果全组病例,完全消退（CR）5例,部分消退（PR）33例,病情稳定（SD）12例,病情进展（PD）4例,总有效（CR＋PR）率67.9%（38/56）;1,2,3年总生存率分别为62.5%（35/56）、41.7%（23/56）和33.9%（19/56）,中位生存期为23个月。结论三维适形放射治疗中期原发性肝癌有较好的疗效,放疗反应可以耐受。Objective To explore the value of three-dimensional conformal radiotherapy in the treatment of hepatocellular carcinoma in the middle stages. Methods From Jan2002 to.Dec 2006, 56 patients with hepatocellular carcinoma in middle stages were treated by 3-DCRT with RAHD7.0 3-D plan system , radiated by 6MV X-ray, with dose range from 40Gy to 65Gy in 16-26 fractions completed in a course of 4 weeks to 6 weeks. Results Three months after irradiation, the overall immediate rate （CR＋PR） was 67.9% （CR 8. 9%, PR 58. 9%）,The 1-,2-and 3-year survival rate were 62.5%（35/56）, 41.7% （23/56） and 33.9%（19/56）, respectively. The middle survival time is 23 months. Conclusion 3-DCRT is an effective methods in the middle stage of hepatices- llular carcinoma.

关 键 词：肝肿瘤 三维适形放射治疗 

分 类 号：R735.7[医药卫生—肿瘤;医药卫生—临床医学]